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Background: Marinesco-Sjögren syndrome (MSS) is an autosomal recessive multisystem disorder characterized by
the tetralogy of cerebellar ataxia, congenital cataracts, intellectual disability, and progressive muscle weakness due
to myopathy. MSS is extremely rare, and its clinical, pathological, and genetic features are not yet fully understood.
Methods: We conducted a nationwide, questionnaire-based survey on MSS in Japan and carefully reviewed the
medical records of 36 patients suspected of having this disease. In addition, pathological examinations of muscles,
sequence and haplotype analysis in SIL1 were performed.
Results: The patients had been examined between the ages of 2 and 52 years. Delayed psychomotor development
and cataracts from early childhood were observed in all patients, whereas no life-threatening events were observed.
Mutations in SIL1 were identified in 24 of the 27 patients tested, and 43 of the 48 chromosomes possessed the SIL1
c.936dupG (p.Leu313fs) mutation. The haplotype analysis revealed that 31 of the 32 chromosomes (96.9%) with the
c.936dupG mutation had the same haplotype.
Conclusions: The results of haplotype analysis suggested the presence of a founder effect. The clinical features of
patients without SIL1 mutations were indistinguishable from those with SIL1 mutations, suggesting the genetic
heterogeneity of MSS.
Keywords: Marinesco-Sjögren syndrome (MSS), SIL1, Founder effect, Cataracts, Intellectual disability, Ataxia, Rimmed
vacuolar myopathyBackground
Marinesco-Sjögren syndrome (MSS; OMIM 248800) is
an autosomal recessive multisystem disorder clinically
characterized by the tetralogy of cerebellar ataxia, con-
genital cataracts, intellectual disability, and progressive
muscle weakness due to myopathy [1-3]. Additional clin-
ical features, including short stature, hypergonadotropic
hypogonadism [4], and strabismus [5], are also observed.
Mutations in SIL1 (Gene ID: 64374) were reported to
be causative for MSS [6,7]. This gene encodes SIL1, also
known as BiP-associated protein (BAP), which is an endo-
plasmic reticulum (ER)-resident protein. Bip is an HSP70
chaperone family member located in the ER, and plays a* Correspondence: yhayashi@tokyo-med.ac.jp
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unless otherwise stated.key role in protein quality control. SIL1 regulates the
ATPase cycle of BiP for proper protein folding [8,9].
SIL1-deficient woozy mutant mice exhibit progressive
ataxia caused by the loss of Purkinje cells via ER stress [10].
MSS is an extremely rare disease, and very few cases
have been reported. In this study, we performed a na-
tionwide, questionnaire-based survey on MSS with the
aim of characterizing its prevalence, clinical features,
natural history, muscle pathological findings, and muta-
tion status.Methods
All clinical materials used in this study were obtained
for diagnostic purposes with written informed consent.
All surveys and experiments performed in this study
were approved by the Ethical Committee of the National
Center of Neurology and Psychiatry.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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To elucidate the clinical characteristics of MSS, we
conducted a nationwide, questionnaire-based survey in
Japan. The first set of questionnaires, which focused on
the experience of treating patients suspected of having
MSS, was sent to a total of 5,452 Japanese specialists for
neurology or pediatric neurology. The second set of ques-
tionnaires, which focused on the clinical information of
patients with suspected MSS, was sent to their attending
physicians. These patients’ medical records were carefully
reviewed by 2 of our specialists (M.G., H.K.).
Histochemistry
Biopsied muscle specimens were flash-frozen in isopentane
cooled in liquid nitrogen. Transverse serial frozen sections
of 10 μm in thickness were subjected to various types of
histochemical staining, including hematoxylin and eosin
(H&E), modified Gomori-trichrome (mGT), and ATPases.
We obtained biopsied skeletal muscles from a total of 17
unrelated patients clinically suspected of having MSS.
Sequence analysis of SIL1
Genomic DNA was extracted from either frozen muscle
or peripheral blood lymphocytes using standard pro-
tocols. The PCR primers were designed to amplify all the
exons of SIL1 together with their flanking intronic regions.
The primer sequences are available upon request. Direct
sequencing was performed using the BigDye Terminator
v3.1 Cycle Sequencing system and an ABI3100 automated
Genetic Analyzer (Applied Biosystems, Foster City, CA).
The sequence data obtained were analyzed using the
SeqScape (Applied Biosystems) program and compared
with the genomic sequence of SIL1 in the database
(NM_022464). Genetic analysis was performed on DNA
from 27 unrelated patients and the parents of 3 of them.
Two hundred control chromosomes from healthy indi-
viduals were examined for each novel mutation in SIL1
by direct sequencing.
Haplotype analysis of SIL1
For the haplotype analysis of the SIL1 genomic region, we
performed direct sequencing of the following 11 common
single nucleotide variants (SNVs) in the Japanese popu-
lation: rs11748097, rs929775, rs10045761, rs1433008, rs1
1958050, rs7717375, rs7722413, rs3763016, rs6596456,
rs700629, and rs12653845 (http://www.ncbi.nlm.nih.gov/
SNP/). Samples from 21 patients homozygous for the
common c.936dupG mutation, the parents of 3 patients,
and 92 control Japanese individuals were analyzed.
Results
Patients
A total of 1,875 responses (34.4% response rate) were re-
ceived to the first set of questionnaires. The second setof questionnaires was sent to a total of 37 attending
physicians (2.0%) who had treated patients suspected of
having MSS. The detailed clinical records of a total of 36
patients were carefully reviewed. The shortfall in the
number of patients was due to an overlap of 1 case.
Sequence analysis of SIL1
Frozen muscle or peripheral blood lymphocytes were
obtained from 27 of the 36 patients suspected of having
MSS, for genetic analysis. Mutations in SIL1 were identi-
fied in 24 out of the 27 patients. Twenty-one patients
were homozygous for the previously reported c.936dupG
(p.Leu313fs) mutation in exon 9. Patient 4 was homozygous
for the previously reported c.603_607del5 (p.Glu201fs)
mutation in exon 6 [11]. Patient 12 was homozygous for
the previously reported c.331C > T (p.Arg111X) mutation
in exon 4 [6,7]. Patient 17 was a compound heterozygote
for the novel c.617_618TC >AA (p.Leu206Glu) mutation
in exon 6 and the c.936dupG (p.Leu313fs) mutation in
exon 9 [12]. All mutations except for p.Leu206Glu are
predicted to induce premature termination. Mutation of
Leu206, which is highly conserved among species, was
predicted to exert a deleterious impact on protein function
by the Polymorphism Phenotyping v2 (PolyPhen-2; http://
genetics.bwh.harvard.edu/pph2/) and the Sorting Intoler-
ant From Tolerant software (SIFT: http://sift.bii.a-star.edu.
sg/). None of these nucleic acid changes were found in the
200 chromosomes from healthy Japanese controls or in
the Japanese Single Nucleotide Polymorphisms database
(http://snp.ims.u-tokyo.ac.jp/index_ja.html).
Haplotype analysis of SIL1
The SIL1 c.936dupG mutation was identified in 43 of
the 48 chromosomes (89.6%) in our cohort. The patients
carrying this mutation were reported from different
areas in Japan. To determine whether this was a result
of a founder effect, we performed a haplotype analysis
using 11 SNVs within or close to SIL1. The results
revealed that 31 of the 32 chromosomes (96.9%) with the
c.936dupG mutation had the same haplotype (P1-P24,
Table 1). This haplotype was only found in 18 of the 184
chromosomes (9.8%) from the control group, suggesting a
founder effect, although 1 chromosome from Patient 1 had
a different haplotype.
Clinical features
Table 2 and Additional file 1: Table S1 show a clinical
summary of the patients in our series.
The age at which the examination was performed in
the 24 patients (10 men and 14 women) with SIL1 muta-
tions varied from 2 to 52 (mean = 20.1 ± 18.1) years.
Bilateral cataracts requiring prompt surgical intervention
had appeared and rapidly progressed in all 24 patients at
the mean age of 3.5 ± 1.2 years. Strabismus was also
Table 1 Haplotype analysis
rs No rs11748097 rs929775 rs10045761 */# rs1433008 rs11958050 rs7717375 @ rs7722413 rs3763016 rs6596456 rs700629 rs12653845
JPT A: 0.24 G: 0.18 A: 0.15 C: 0.15 A: 0.76 A: 0.82 C: 0.11 G: 0.11 A: 0.13 A: 0.14 G: 0.11
P1 C/A T/G G N T A/G A H T/C C/G A A T
P2 C T G N T A A H T C A A T
P3 C T G N T A A H T C A A T
P5 C T G N T A A H T C A A T
P6 C T G N T A A H T C A A T
P7 C T G N T A A H T C A A T
P9 C T G N T A A H T C A A T
P10 C T G N T A A H T C A A T
P13 C T G N T A A H T C A A T
P14 C T G N T A A H T C A A T
P15 C T G N T A A H T C A A T
P16 C T G N T A A H T C A A T
P18 C T G N T A A H T C A A T
P20 C T G N T A A H T C A A T
P21 C T G N T A A H T C A A T
P24 C T G N T A A H T C A A T
P12 C T G * T A A N T C A A T
P4 C T G # T A A N T C G C T
P25 C/A T/G G/A N T/C A/G A/G N T C G C T/G
P26 C/A T/G G/A N T/C A/G A/G N T C G C T/G
P27 C T G N T A A N T C G C T
@: c.936dupG, *: c.331C > T, #: c.603_607del, JPT: Japanese frequency.




















Table 2 Clinical summary of patients
SIL1 mutations Positive (n = 24) Negative (n = 3) Not examined (n = 9)
Ocular involvements
Cataracts 24/24 (100%), 2y-6y 3/3 (100%) 9/9 (100%)
Strabismus 10/18 (56%) 1/3 (33%) 5/7 (71%)
Motor functions
Muscle weakness 21/22 (95%), 2y-52y 3/3 (100%) 9/9 (100%)
Development
Head control 21/21 (100%), 4 m-18 m 5 m-8 m 4 m-7 m
Sit 20/20 (100%), 10 m-36 m 12 m-18 m 12 m-36 m
Stand with support 16/20 (80%), 1y-4y 15 m, 24 m 15 m-6y
Walk with support 16/20 (80%), 2y-22y 2/2 (100%) 15 m, 24 m 3/3 (100%) 15 m-6y
Loss of ambulation 5/16, 13y-28y
Cerebellar signs
Hypotonia 21/24 (88%) 3/3 (100%) 9/9 (100%)
Ataxia 16/24 (67%), 2y-52y 2/3 (100%) 6/8 (75%)
Nystagmus 11/24 (46%), 2y-45y 0/3 5/8 (63%)
Dysarthria 8/24 (33%), 2y-48y 2/3 (67%) 4/9 (44%)
Psychomotor delay 20/22 (91%), IQ(DQ):24-100 3/3 (100%) 9/9 (100%)
Hypogonadism 3/8 (38%) 0/1 2/3 (67%)
Skeletal abnormalities
Short stature 12/18 (67%), 1/3 (33%) 3/8 (38%)
Spinal deformities 8/22 (36%) 1/3 (33%) 3/7 (43%)
Flat foot 7/22 (32%) 0/3 1/7 (14%)
Short fingers 5/22 (23%) 0/3 2/8 (25%)
Others
Serum CK (IU/L) 28-2000 144-3010 95-600
Cerebellar atrophy 19/19 (100%) 3/3 (100%) 9/9(100%)
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http://www.ojrd.com/content/9/1/58observed in 55.6% (10/18) of the patients. Cerebellar
signs included hypotonia (21/24; 88%), ataxia (16/24;
67%), nystagmus (11/24; 46%), and dysarthria (8/24;
33%) were seen. Brain MRI demonstrated marked atro-
phy of the cerebellum, particularly the vermis, in all the
patients examined (19/19). Mild to moderate intellectual
disability, diagnosed by intelligence quotient/develop-
mental quotient between 35 and 70, was seen in 91%
(20/22) of the patients. Acquisition of meaningful words
occurred at the age of 2.0 ± 0.8 years, and most of the
patients had required special-needs education. Muscle
weakness was observed in 95% (21/22) of the patients,
with delays in motor milestones. Head control was first
seen in all the patients at a certain time point between 4
and 18 (mean = 7.8 ± 3.7) months, and sitting at a certain
time point between 10 and 36 (mean = 20.0 ± 8.7) months.
Eighty percent (16/20) of the patients could stand with
support at a certain point between the ages of 1 and
4 years, and walk with support at a certain point between
the ages of 2 and 22 (mean = 5.8 ± 2.6) years; however,
none of the patients acquired the ability to walk inde-
pendently. Muscle weakness was slowly progressive
and predominantly in the proximal muscles, with the
patients becoming wheelchair-bound at a certain time
point between the ages of 13 and 28 (mean = 17.4 ± 6.3)
years. Serum creatine kinase levels were normal to
moderately elevated (28–2000, mean = 389 ± 464; nor-
mal < 200 IU/L). Short stature (< −2 SD) was seen in
67% (12/18, mean = −3.6 SD) of the patients, and spinal
deformity (8/22; 36%), flat foot (7/22; 32%), and short
fingers (5/22; 23%) were also reported. Hypogonado-
tropic hypogonadism was seen in 3 of 8 (38%) patients
(1 with microtestis, 2 with amenorrhea). No marked
clinical differences were observed among patients with
different SIL1 mutations. No patient had cardiac and
respiratory problems.
The 3 patients with no SIL1 mutation (Patients 25, 26,
and 27) and the 9 genetically unexamined patients showed
clinical features indistinguishable from the patients with
SIL1 mutations, including cerebellar signs with cerebellarFigure 1 Modified gomori trichrome stain of the biopsied skeletal mu
vacuoles (arrow, A), whereas no vacuole is seen in a patient without SIL1 matrophy on brain images, intellectual disability, congenital
cataracts, and muscle weakness. Elevation of serum CK
levels was also seen in 2 patients (Table 2).
Pathological findings of skeletal muscles
Biopsied skeletal muscles were obtained from 16 patients
with SIL1 mutations and one patient without (Patient 27).
All muscle specimens showed myopathic changes of vari-
ation in fiber size and endomysial fibrosis. A few necrotic
and regenerating fibers were seen in some patients with
SIL1 mutations. No neurogenic changes, including fiber
type grouping and grouped atrophy, were observed in any
of the patients. Importantly, scattered rimmed vacuoles
(RVs) were seen in all 16 patients with SIL1 mutations, but
not in the patient without (Figure 1).
Discussion
We conducted a nationwide, questionnaire-based survey
to clarify the prevalence, clinical and pathological character-
istics, and long-term course of MSS in Japanese patients.
The total number of patients with MSS was only 36.
From a clinical point of view, it is important to carry
out careful ophthalmological examination of MSS pa-
tients at a young age if visual acuity is to be preserved,
as the cataracts characteristic of MSS usually appear
abruptly and develop rapidly from an early age [13,14].
Indeed, all of the patients in our present series required
early and prompt surgical intervention. Marked cerebellar
atrophy on brain MRI is another characteristic of this dis-
ease, however cerebellar ataxia can be difficult to identify,
especially in younger patients with muscle weakness. Skel-
etal muscle weakness is also a prominent characteristic.
Almost all the MSS patients with SIL1 mutations in this
series had muscle weakness initially noticed as a delayed
motor milestone, which was detected at an earlier age
than cataracts, as reported previously [3,15,16]. Regarding
muscle biopsy, myopathic changes, including RV forma-
tion are a characteristic of patients with SIL1 mutations.
RVs are not disease-specific, and are often seen in adult-
onset chronic myopathies such as inclusion body myositis,scles. A muscle from a MSS patient with SIL1 mutation shows rimmed
utation (B). Bar = 20 μm.
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trophy, and myofibrillar myopathies. They are rarely ob-
served, however, in childhood-onset myopathies. The
presence of RVs in muscle biopsy tissue can be helpful in
formulating an early diagnosis of MSS, allowing the oph-
thalmologist to perform surgery for cataracts to prevent
total visual loss. The life prognosis of MSS appears to be
comparatively good, as respiratory, cardiac, and swallow-
ing functions are well preserved, even in the patients who
are over 50 years of age.
Most of the reported SIL1 gene mutations have been
predicted to induce premature termination and loss of
function of SIL1. Based on a putative model of SIL1-BiP
interaction, the C-terminal 5 amino acids of SIL1 are
thought to play a key role in its association with BiP [17].
This concept is further strengthened by the fact that the
p.Arg111X, p.Glu201fs, and p.Leu313fs mutations cause
the generation of SIL1 proteins lacking the C-terminal
region. Complete loss of function due to nonsense-
mediated mRNA decay should also be considered. On
the other hand, Leu206 in exon 6 is well preserved
among species, and the novel nonsynonymous muta-
tion p.Leu206Glu is predicted to exert a deleterious im-
pact on protein function by both SIFT and PolyPhen2.
The c.936dupG (p.Leu313fs) mutation in SIL1, which
was first reported from Japan [12], is highly common in
Japanese MSS patients. Haplotype analysis revealed
that whereas 96.9% of chromosomes from MSS patients
possessing the c.936dupG mutation had the same
haplotype, less than 10% of the chromosomes of the
controls did so, suggesting a founder effect.
The results of this study also strongly suggest the genetic
heterogeneity of MSS. Three of the 27 patients (11.1%) had
no SIL1 mutation, but demonstrated the cardinal features
of MSS, including congenital cataracts, ataxia, intellectual
disability, and myopathy. We could not exclude the pos-
sibility of the mutation occurred in the promoter or
other non-coding region of SIL1 in these 3 patients.
Previous reports also showed that approximately one-
half of the MSS patients were genetically diagnosed as
MSS from mutations in SIL1 [7,16]. The absence of RVs
in the muscle biopsy tissue of one patient with no SIL1
mutation suggests the existence of a different disease
mechanism(s) in such patients. Further analysis is
required to identify the other causative genes for MSS.Conclusions
MSS is an extremely rare disease, but a possible founder
effect was present in Japan. The life prognosis of MSS is
comparatively good, and early diagnosis is important for
prevention of a total visual loss. Other causative genes
for MSS can cause indistinguishable clinical features via
different disease mechanisms.Additional file
Additional file 1: Table S1. Clinical findings of each patient with or
without SIL1 mutations.
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